Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Italy Fines Apple €98.6 Million Over App Store Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
PETALUMA, Calif., Jan. 26, 2017 -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal third quarter 2017, ended December 31, 2016, will be released after the U.S. markets close on February 9, 2017. The earnings release will be followed by a conference call at 1:30 p.m. PST on February 9, 2017, to discuss fiscal third quarter results.
Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at http://ir.oculusis.com/events.cfm.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 47934612. A webcast replay will be available on the site at http://ir.sonomapharma.com/events for one year following the call.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com
Media and Investor Contact: Sonoma Pharmaceuticals, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
